Ribociclib Improves Progression-Free Survival for Some Women with Metastatic Breast Cancer
A summary of interim results from a phase III trial testing ribociclib plus letrozole (Femara®) as a first-line treatment for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Media Type: Html
- SourceUrl: https://www.cancer.gov/publishedcontent/syndication/1066661.htm
- Syndication ID: 19262
- Language: English
- Source: National Cancer Institute (NCI)
- Date Syndication Captured: Monday, March 23, 2020 at 07:12 PM
- Date Syndication Updated: Thursday, July 23, 2020 at 09:12 AM
Embed Code Snippet
To get the embed code snippet please Login.
